Inovio Pharmaceuticals (INO) Convertible Debt (2019 - 2022)

Inovio Pharmaceuticals has disclosed Convertible Debt across 4 years of filings, most recently posting $16.6 million for Q4 2022.

• In Q4 2022, Convertible Debt rose 11.06% year-over-year to $16.6 million; the TTM figure through Dec 2022 stood at $16.6 million (up 11.06% YoY), while the FY2022 annual figure was $16.6 million, up 11.06% from the prior year.
• Convertible Debt came in at $16.6 million for Q4 2022 at Inovio Pharmaceuticals, up from $16.3 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $65.8 million in Q2 2020 to a low of $14.1 million in Q1 2021.
• Average Convertible Debt over 4 years is $31.7 million, with a median of $16.4 million recorded in 2022.
• Year-over-year, Convertible Debt tumbled 77.97% in 2020 and climbed 15.2% in 2022.
• Over 4 years, Convertible Debt stood at $64.2 million in 2019, then plunged by 77.97% to $14.1 million in 2020, then climbed by 5.8% to $15.0 million in 2021, then advanced by 11.06% to $16.6 million in 2022.
• Per Business Quant data, the three most recent Convertible Debt figures were $16.6 million in Q4 2022, $16.3 million in Q3 2022, and $16.5 million in Q2 2022.